Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Core Insights - The company experienced a strong first quarter driven by pent-up demand from large pharmaceutical companies [1] - The second quarter also exceeded guidance, indicating continued positive performance [1] - There is a notable stability with large pharmaceutical and biotech companies, while smaller biotech firms are facing challenges in accessing capital [1] - The company is actively working on reducing its cost structure, targeting approximately $75 million in savings annually for several years [1]